Resistance to cisplatin, one of the most widely used chemotherapeutics, is often reported in prostate cancer. In a study published in ACS Central Science, the authors found that Platin-L, a cisplatin prodrug, inhibits fatty acid oxidation (FAO) in prostate cancer cells by interacting with carnitine palmitoyltransferase 1A (CPT1A), a crucial enzyme in fat metabolism. Prostate cancer cells switch from glycolysis to FAO to support tumour growth. Thus, Platin-L-mediated disruption of FAO in these cells restored a glucose-dependent chemosensitive state. Importantly, Platin-L-loaded nanoparticles delivered orally to mouse models of prostate cancer led to a substantial tumour reduction in mice treated with cisplatin. These results suggest a potentially promising approach to improve response in patients with cisplatin-resistant tumours.